WELLESLEY, Mass., June 1 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Arthur M. Krieg, M.D., Executive Vice President, Research and Development and Chief Scientific Officer will be presenting a corporate update at the upcoming Bear Stearns 3rd Annual Boston Biotech Confab meeting at 8:50am EDT on June 7, 2007 at the Boston Marriott Copley Place.
Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the “Investor Events” page in the Investor Center section of the Coley website for two weeks until June 21, 2007
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government. For further information on Coley Pharmaceutical Group please visit www.coleypharma.com.
Coley Pharmaceutical Group, Inc.
CONTACT: Susan Hager, Senior Director, Investor Relations and CorporateCommunications of Coley Pharmaceutical Group, +1-781-431-9079,shager@coleypharma.com; or Karen L. Bergman, +1-650-575-1509,kbergman@bccpartners.com, or Michelle Corral, +1-415-794-8662,mcorral@bccpartners.com, both of BCC Partners (US), for ColeyPharmaceutical Group
Web site: http://www.coleypharma.com/
